Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata

12 Aug 2022

Abstract excerpt

von Hippel-Lindau (VHL) disease is a rare hereditary cancer syndrome that causes a predisposition to renal clear-cell carcinoma, hemangioblastoma, pheochromocytoma, and autosomal-recessive familial polycythemia. pVHL is the substrate conferring subunit of an E3 ubiquitin ligase complex that binds to the three hypoxia-inducible factor alpha subunits (HIF1-3α) for polyubiquitylation under conditions of normoxia,...

Topics

Join the communities discussing this publication.

Acute Myeloid Leukemia Research
Adrenal and Paraganglionic Tumors
Cancer, Hypoxia, and Metabolism

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 36040300
DOI: 10.7554/elife.80774

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmataPMID 36040300Read ↗

Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.Semantic proximity Read ↗

The VHL tumor suppressor: master regulator of HIF.Semantic proximity Read ↗

von Hippel-Lindau disease: recent advances and therapeutic perspectives.Semantic proximity Read ↗

Von Hippel–Lindau Disease: Molecular Pathological Basis, Clinical Criteria, Genetic Testing, Clinical Features of Tumors and TreatmentSemantic proximity Read ↗

Recent advances in etiology and treatment of von Hippel-Lindau Disease (VHLD).Semantic proximity Read ↗

von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.Semantic proximity Read ↗

Von Hippel-Lindau disease.Semantic proximity Read ↗

The von Hippel-Lindau tumor suppressor gene.Semantic proximity Read ↗

Genetics, Pathophysiology, and Current Challenges in Von Hippel-Lindau Disease TherapeuticsSemantic proximity Read ↗

Two sides to every story: the HIF-dependent and HIF-independent functions of pVHLSemantic proximity Read ↗

The VHL tumor suppressor and HIF: insights from genetic studies in mice.Semantic proximity Read ↗

The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.